Austar Lifesciences Valuation
Is 6118 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6118 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6118's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6118's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6118?
Key metric: As 6118 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6118's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | CN¥1.55b |
| Market Cap | CN¥314.65m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | -430.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6118's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.3x | ||
1873 Viva Biotech Holdings | 0.9x | n/a | HK$1.9b |
8225 China Health Group | 6.7x | n/a | HK$177.2m |
2576 Zhejiang Taimei Medical Technology | 4.7x | 13.6% | HK$2.9b |
1521 Frontage Holdings | 1x | 15.9% | HK$2.0b |
6118 Austar Lifesciences | 0.2x | n/a | HK$338.3m |
Price-To-Sales vs Peers: 6118 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (3.3x).
Price to Sales Ratio vs Industry
How does 6118's PS Ratio compare vs other companies in the Asian Life Sciences Industry?
Price-To-Sales vs Industry: 6118 is good value based on its Price-To-Sales Ratio (0.2x) compared to the Asian Life Sciences industry average (4.2x).
Price to Sales Ratio vs Fair Ratio
What is 6118's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6118's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.29
7D
-5.1%
1Y
n/a
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.29
7D
-5.1%
1Y
n/a
Innovent Biologics
HK$58.8b
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
1801
HK$35.90
7D
-4.9%
1Y
-18.1%